Path to Prevention Platform Trial in Early-Stage Neuronal Alpha-Synuclein Disease: Study Design

The development of biologically targeted therapeutics (BTTs) that slow Parkinson's disease progression has been hampered by a reliance on testing interventions in clinically defined populations with already advanced pathobiology. Publications on the biological definition and classification of neuronal a-synuclein disease (NSD), and the development of the NSD integrated staging system (NSD-ISS), have generated a framework for identifying individuals with NSD prior to the emergence of a clinically defined syndrome. Path to Prevention (P2P) is a phase 2A, randomized, double-blind, placebo-control

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.